Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Efficacy of Vadadustat for the Treatment of CKD-Related Anemia within and outside the United States.

Journal of the American Society of Nephrology : JASN·2025
Same author

Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis.

Journal of the American College of Cardiology·2025
Same author

S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE).

Future oncology (London, England)·2025
Same author

Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease.

Diabetes care·2025
Same author

Total Anatomical Nasal Skeletal Reconstruction Using a New Autologous Graft: The Tent Shaped Fibular Contoured Bone Graft.

Aesthetic plastic surgery·2025
Same author

Evaluating Performance of the Surprise Question to Predict 12-Month Mortality in Patients With End-Stage Liver Disease.

The American journal of hospice & palliative care·2025

Related Experiment Videos

Effects of statins on renal function.

Rajiv Agarwal1

  • 1Indiana University School of Medicine, Richard L. Roudebush [corrected] VA Medical Center, 1481 W Tenth St (111N), Indianapolis, IN 46202, USA.

Mayo Clinic Proceedings
|November 3, 2007
PubMed
Summary

Statins may slow kidney function decline and reduce protein in urine for chronic kidney disease (CKD) patients. Further research is needed to confirm cardiovascular benefits in this high-risk population.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Patients with chronic kidney disease (CKD) face a higher risk of cardiovascular disease (CVD) mortality.
  • Dyslipidemia is common in CKD, potentially worsening cardiovascular risk and disease progression.
  • Statins, used for lipid reduction, may offer kidney protection through cholesterol-dependent and independent pathways.

Purpose of the Study:

  • To review the evidence on statin therapy's effects on kidney function and proteinuria in CKD patients.
  • To assess the current understanding of statins' role in reducing cardiovascular risk in CKD.
  • To highlight the need for further research on cardiovascular outcomes in CKD patients using statins.

Main Methods:

  • Review of subgroup analyses from major clinical trials.

Related Experiment Videos

  • Meta-analyses of smaller clinical trials involving statin therapy in CKD.
  • Examination of existing literature on statins, dyslipidemia, and cardiovascular outcomes in CKD.

    • Main Results:

    • Statin therapy appears to slow the decline of glomerular filtration rate (GFR) in CKD patients.
    • Evidence suggests statins can reduce proteinuria in individuals with CKD.
    • Statins are known to decrease cardiovascular morbidity and mortality in various populations, but conclusive data for CKD is pending.

    Conclusions:

    • Statins show promise in preserving kidney function and reducing proteinuria in CKD.
    • While statins benefit cardiovascular health broadly, their specific impact on cardiovascular outcomes in CKD requires more investigation.
    • Ongoing studies are crucial for establishing the role of statins in managing cardiovascular risk for CKD patients.